The Texas A&m University System

Board of Trustees of the University of Arkansas

University of Guelph

Luc Berghman

Billy M Hargis

Sherryll Layton

Lisa Bielke

Olivia B Faulkner

Walter G Bottje

John R Barta

Young Min Kwon

Kimberly Cole

Mandy Cox

Srichaitanya Shivaramaiah

Neil R Pumford

Guillermo Tellez

Waithaka Mwangi

Daad Abi-Ghanem

Surya Waghela

Leona Nicole Calhoun

Saeed El-Ashram

Said El-Ashram

Walter Bottje

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

Compositions and methods of enhancing immune responses toor limitinginfection

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.

Mosaic chimeric viral vaccine particle

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.

Compositions and methods of enhancing immune responses to enteric pathogens

Vaccines comprising TRAP polypeptides andvectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.

Compositions and methods of enhancing immune responses to

[object Object]

Compositions and methods of enhancing immune responses to Eimeria

Provided herein are13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.

Compositions and methods of enhancing immune responses

Growing community of inventors

College Station, TX, United States of America

Luc Berghman